首页|期刊导航|中国药物经济学|板蓝根滴眼液的临床综合评价

板蓝根滴眼液的临床综合评价OA

Clinical Comprehensive Evaluation of Radix Isatidis Eye Drops

中文摘要英文摘要

对板蓝根滴眼液进行综合评价,以期为该中成药的临床合理应用提供参考.收集板蓝根滴眼液上市前后的证据资料,从安全性、有效性、经济性、传承与创新性、适宜性、可及性共 6 个维度对板蓝根滴眼液进行综合性评价.板蓝根滴眼液在治疗急性细菌性结膜炎或病毒性角膜炎等方面有显著疗效;临床研究中显示其不良反应轻微,不良反应发生率低,安全性较高;板蓝根滴眼液已纳入国家医保目录,价格适中.本品为外用滴眼剂,使用与携带方便,患者依从性较好;药品说明书、包装、标签等符合现行规定.板蓝根滴眼液的销售遍及多个省市自治区,可获得性较高.板蓝根滴眼液临床安全有效,质量达标可控,价格适中;其使用方便,有较好的适宜性.

The comprehensive evaluation of Radix Isatidis eye drops was carried out in order to provide reference for the clinical rational application of this patent Chinese medicine.The evidence data before and after the launch of Radix Isatidis eye drops were collected,and a comprehensive evaluation was made on Radix Isatidis eye drops from six dimensions:safety,effectiveness,economy,inheritance and innovation,suitability and accessibility.Radix Isatidis eye drops is effective in treating acute bacterial conjunctivitis or viral keratitis.Clinical studies have shown mild adverse reactions.The incidence of adverse reactions is low and the safety is high.Radix Isatidis eye drops have been included in the national medical insurance directory and the price is moderate.It is easy to use and carry.The instructions,packaging and labels of drugs conform to the current regulations.Radix Isatidis eye drops are sold in many provinces and autonomous regions with high availability.Radix Isatidis eye drops are clinically safe and effective.The quality is up to standard and controllable.The price is moderate.It is easy to use and has good suitability.However,there is little evidence of high quality studies on safety,effectiveness and economy,and additional studies should be conducted.

李慧;李佳怡;何婷;马丽娜;顾媛媛;郭媛媛;赵薇;曹俊岭

北京中医药大学中药学院,北京 100029||首都医科大学附属北京中医医院肿瘤科,北京 100010北京中医药大学东直门医院药学部,北京 100700北京中医药大学东方医院药学部,北京 100078北京中医药大学东方医院药学部,北京 100078北京中医药大学东方医院药学部,北京 100078北京中医药大学中药学院,北京 100029北京中医药大学东方医院药学部,北京 100078北京中医药大学中药学院,北京 100029||北京中医药大学东直门医院洛阳医院,河南 洛阳 471003

中医学

板蓝根滴眼液中成药临床综合评价

Radix Isatidis eye dropsChinese patent medicineClinical comprehensive evaluation

《中国药物经济学》 2025 (2)

17-20,26,5

10.12010/j.issn.1673-5846.2025.02.003

评论